The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]
A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]
A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]
A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]
The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]
The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.
After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.
The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]
In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]
Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.
A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.
The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]
In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.
On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.
In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.
The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]
The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.
The graduate student at the University of Michigan provided insight on the ways to expand the current knowledge about the disparities among races and genders in sleep quality and long-term cognitive outcomes. [WATCH TIME: 3 minutes]
In the comparator study between ponesimod and teriflunomide, the risk of both 12- and 24-week confirmed disability accumulation at week 108 was significantly different between MAGNIMS score groups.
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Afsara Zaheed; Richard Bogan, MD, FCCP, FAASM; and Ruth Benca, MD, PhD. [LISTEN TIME: 18 minutes]
Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.
The associate clinical professor at the University of South Carolina School of Medicine discussed the strides, but also challenges still in treating patients with narcolepsy. [WATCH TIME: 2 minutes]
Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.
The associate professor at the North Carolina Agricultural and Technical State University provided insight on the widespread feasibility of a new initiative that aims to teach and attract young professionals to the MS field. [WATCH TIME: 4 minutes]
Galit L. Dunietz, PhD, MPH, assistant professor of neurology, University of Michigan, provided insight on women’s health, menopause cycles, and how sleep can have a direct impact on long-term cognitive health.
In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.
